Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Manufacturing Legislation Platform Technologies

Continuous Manufacturing Centers Of Excellence Measure Resurfaces In US House

  • News

Executive Summary

Stand-alone bill headed for Senate, where it fared poorly in coronavirus response legislative packages.

You may also be interested in...



Continuous Manufacturing Back In Second Act

House tries again to promote advanced technology for the return of pharmaceutical manufacturing to the US in post-COVID-19 era.

Generic Firms Want Congress To Build On CARES Act To Prevent Critical Drug Shortages

The association for manufacturers of generics and biologics calls for public sector investment in priority medicines.

US Forming Industry Consortia To Prepare For Future Pandemics And Global Supply Chain Disruptions

HHS agencies look to build on COVID-19 experience by developing quicker public/private responses to pandemics and supply chain threats.

Table

View full table

Topics

Tags:
Manufacturing Legislation Platform Technologies
UsernamePublicRestriction

Register

PS142966

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By